• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Serina Therapeutics Inc.

    9/26/25 12:19:07 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SER alert in real time by email
    DEFA14A 1 serina-defa14a2025proxycov.htm DEF 14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    SCHEDULE 14A
    (Rule 14a-101)
    INFORMATION REQUIRED IN PROXY STATEMENT
    SCHEDULE 14A INFORMATION
    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
    Filed by the Registrant ý
    Filed by a Party other than the Registrant ☐
    Check the appropriate box:
    ☐
    Preliminary Proxy Statement
    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☒
    Definitive Proxy Statement
    ý
    Definitive Additional Materials
    ☐
    Soliciting Material Pursuant to §240.14a-12
    Serina Therapeutics, Inc.
    (Name of Registrant as Specified in Its Charter)
    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):
    ý
    No fee required.
    ☐
    Fee paid previously with preliminary materials.
    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.




    imagea.jpg



    image1a.jpg

    Get the next $SER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SER

    DatePrice TargetRatingAnalyst
    7/14/2025$15.00Buy
    H.C. Wainwright
    More analyst ratings

    $SER
    SEC Filings

    View All

    Serina Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

    12/10/25 4:17:35 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

    11/13/25 6:05:15 AM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Serina Therapeutics Inc.

    10-Q - Serina Therapeutics, Inc. (0001708599) (Filer)

    11/13/25 6:03:31 AM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

    HUNTSVILLE, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ PlatformTM drug optimization technology, today announced the appointment of Joshua Thomas, Ph.D., as Vice President and Head of Chemistry. He will oversee internal and external chemistry efforts to optimize POZ-based candidates, supporting efficient translation from discovery through development. Prior to joining Serina, Dr. Thomas served in progressive scientific leadership roles at Mersana Therapeutics,

    12/11/25 4:15:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

    – Company addresses FDA requests regarding formulation excipient – Global site start-up activities continue, with first-patient-in for registrational Phase 1b study targeted for Q1 2026, subject to FDA feedback HUNTSVILLE, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ PlatformTM drug optimization technology, today announced that it has submitted a complete response to the U.S. Food and Drug Administration's ("FDA") clinical hold letter for SER-252, the Company's

    12/10/25 4:30:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

    HUNTSVILLE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the third quarter ended September 30, 2025, along with key recent updates. Steve Ledger, Chief Executive Officer of Serina, stated, "The FDA's alignment with our plan to advance SER-252 under a 505(b)(2) NDA pathway, and its recognition of the Phase 1b trial as registrational, represents a key milestone for Serina. This outco

    11/13/25 6:10:00 AM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Moreadith Randall exercised 3,555 shares at a strike of $0.06 and sold $11,520 worth of shares (3,555 units at $3.24) (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    12/12/25 12:48:08 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Moreadith Randall exercised 600 shares at a strike of $0.06, sold $4,149 worth of shares (1,245 units at $3.33) and was granted 645 shares (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    12/11/25 4:11:24 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Moreadith Randall exercised 6,500 shares at a strike of $0.06 and sold $23,481 worth of shares (6,500 units at $3.61) (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    12/4/25 7:56:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bailey Gregory bought $17,745 worth of shares (3,866 units at $4.59), increasing direct ownership by 6% to 67,243 units (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    12/19/24 4:05:12 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bailey Gregory bought $6,851 worth of shares (1,137 units at $6.03), increasing direct ownership by 2% to 63,377 units (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    9/24/24 4:30:06 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bailey Gregory bought $88,257 worth of shares (14,388 units at $6.13), increasing direct ownership by 30% to 62,240 units (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    9/20/24 6:59:29 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Serina Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Serina Therapeutics with a rating of Buy and set a new price target of $15.00

    7/14/25 8:54:25 AM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Leadership Updates

    Live Leadership Updates

    View All

    Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

    HUNTSVILLE, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ PlatformTM drug optimization technology, today announced the appointment of Joshua Thomas, Ph.D., as Vice President and Head of Chemistry. He will oversee internal and external chemistry efforts to optimize POZ-based candidates, supporting efficient translation from discovery through development. Prior to joining Serina, Dr. Thomas served in progressive scientific leadership roles at Mersana Therapeutics,

    12/11/25 4:15:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

    - Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors. Dr. Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization

    5/22/25 4:50:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

    HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of development, including high-profile mergers and acquisitions. Dr. Venkatesan most recently served as Chairman, President, and CEO of Angion Biomedica until its merger with Elicio Therapeutics in 2023. He

    2/12/25 4:15:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Financials

    Live finance-specific insights

    View All

    $SER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

    HUNTSVILLE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the third quarter ended September 30, 2025, along with key recent updates. Steve Ledger, Chief Executive Officer of Serina, stated, "The FDA's alignment with our plan to advance SER-252 under a 505(b)(2) NDA pathway, and its recognition of the Phase 1b trial as registrational, represents a key milestone for Serina. This outco

    11/13/25 6:10:00 AM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

    HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the second quarter ended June 30, 2025, along with key recent updates. "We're proud of the momentum we've built across our development programs. With SER-252 on track to enter the clinic later this year and the recent advancement of SER-270 for tardive dyskinesia, we are demonstrating how the POZ Platform can enable differentiated, long-acting therapies across neurologic

    8/11/25 4:30:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

    HUNTSVILLE, July 01, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company, today announced that its Board of Directors has established November 7, 2025, as the date of its 2025 annual meeting of stockholders (the "Annual Meeting"). The time and location of the Annual Meeting will be set forth in the Serina's definitive proxy statement for the Annual Meeting to be filed with the Securities and Exchange Commission (the "SEC"). Because the date of the Annual Meeting represents a change of more than 30 days from the anniversary of Serina's 2024 annual meeting of stockholders, the deadline for stockholder proposals to be submitted pur

    7/1/25 4:15:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Serina Therapeutics Inc.

    SC 13D/A - Serina Therapeutics, Inc. (0001708599) (Subject)

    12/9/24 4:45:59 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Serina Therapeutics Inc.

    SC 13G/A - Serina Therapeutics, Inc. (0001708599) (Subject)

    11/14/24 5:09:38 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Serina Therapeutics Inc.

    SC 13D/A - Serina Therapeutics, Inc. (0001708599) (Subject)

    7/5/24 4:01:13 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care